Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary tuberculosis.

Postgraduate medicine·2017
Same author

Response.

Chest·2014
Same author

A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation.

Respiratory medicine·2014
Same author

Tiotropium in asthma: a systematic review.

Journal of asthma and allergy·2014
Same author

Counterpoint: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? No.

Chest·2014
Same author

Rebuttal from Drs Colice and Idell.

Chest·2014

Related Experiment Video

Updated: May 31, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Emerging therapeutic options for asthma.

Gene L Colice1

  • 1Washington Hospital Center, 110 Irving St NW, Washington, DC 20010, USA. Gene.Colice@Medstar.net

The American Journal of Managed Care
|July 19, 2011
PubMed
Summary
This summary is machine-generated.

Asthma treatment traditionally uses inhaled corticosteroids (ICSs), but new therapies are emerging for severe cases. Research explores novel pharmacologic and non-pharmacologic options for better asthma control.

More Related Videos

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

Related Experiment Videos

Last Updated: May 31, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

Area of Science:

  • Pulmonology
  • Allergy and Immunology
  • Pharmacology

Background:

  • Asthma involves eosinophilic airway inflammation and elevated immunoglobulin E (IgE).
  • Inhaled corticosteroids (ICSs) are the historical foundation of asthma treatment.
  • ICSs and other therapies do not always achieve adequate asthma control in all patients.

Purpose of the Study:

  • To review current and emerging therapeutic approaches for asthma.
  • To highlight the limitations of traditional asthma treatments.
  • To discuss novel pharmacologic and non-pharmacologic options for severe, persistent asthma.

Main Methods:

  • Review of existing literature on asthma pathophysiology and treatment.
  • Analysis of current clinical guidelines and trial data.
  • Exploration of investigational agents and non-pharmacologic interventions.

Main Results:

  • ICSs are effective for some, but severe asthma often requires additional therapies.
  • Long-acting beta2-agonists, leukotriene modifiers, and anti-IgE antibodies are common add-on treatments.
  • Emerging agents targeting cytokines, phosphodiesterase 4, and oligonucleotides show promise.

Conclusions:

  • Understanding asthma pathophysiology is key to developing novel treatments.
  • Bronchial thermoplasty offers a non-pharmacologic option for difficult-to-control asthma.
  • Future advances in pharmacologic and non-pharmacologic therapies hold promise for severe, persistent asthma.